A phase 1 Single Ascending Dose study of KDS2010 and in healthy young adults and elderly subjects
Latest Information Update: 18 Dec 2024
Price :
$35 *
At a glance
- Drugs Tisolagiline (Primary)
- Indications Alzheimer's disease; Obesity
- Focus Adverse reactions; Pharmacokinetics
- 18 Dec 2024 New trial record
- 11 Dec 2024 Results presented in a Scilex Bio media release
- 11 Dec 2024 According to a Scilex Bio media release, KDS2010 pharmacokinetics, lack of food effect, safety and dose selection have been characterized in Single Ascending Dose and Multiple Ascending Dose Phase 1 clinical trials with 88 healthy young adults and elderly subjects.